• Net cash used in operating activities of $576k in Q3 2025
• Cash and cash equivalents of $61k at quarter end
• Operations being funded by Biortica under Deed of Company Arrangement

Bod Science Ltd has released its Quarterly Appendix 4C Cash Flow Report for the quarter ended 30 September 2025. The company reported a net cash outflow from operating activities of $576k, primarily driven by payments for administration and corporate costs of $1,251k, which included $584k in administration fees and $475k in legal and other fees incurred since the start of the administration period. Receipts from customers were $540k, and payments for product manufacturing and operating costs were $185k. The company had cash and cash equivalents of $61k at the end of the quarter. Bod Science Ltd is currently operating under a Deed of Company Arrangement, and its ongoing trading costs are being partially funded by Biortica Agrimed Limited in accordance with the Heads of Agreement signed on 9 February 2024. The company expects to continue its operations and meet its business objectives under the DOCA arrangement with Biortica's funding support.

The company is operating under a Deed of Company Arrangement, with its operations being funded by Biortica Agrimed Limited in order for a backdoor listing by Biortica to proceed.